

Oncology Today with Dr Neil Love: PARP Inhibition in the Management of Pancreatic Cancer (Presentation Video)**THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.**

- 1. The POLO trial, investigating maintenance therapy with olaparib versus placebo for patients with metastatic pancreatic cancer who had a germline BRCA mutation, demonstrated which of the following outcomes with olaparib?**
 - a. A significant improvement in progression-free survival only**
 - A significant improvement in overall survival only
 - A significant improvement in both progression-free and overall survival
- 2. The Phase II RUCAPANC2 study demonstrated promising activity with maintenance rucaparib after platinum-based chemotherapy in patients with platinum-sensitive advanced pancreatic cancer with which pathogenic mutations?**
 - Germline BRCA mutations only
 - Germline or somatic BRCA mutations only
 - c. Germline or somatic BRCA or PALB2 mutations**
- 3. Which of the following statements is true regarding ATM mutations in patients with pancreatic cancer?**
 - They occur in about 1% of patients and confer lack of sensitivity to platinum-based chemotherapy
 - b. They occur in about 6% of patients and are associated with sensitivity to platinum-based chemotherapy**
- 4. In a study by Shroff and colleagues evaluating rucaparib as monotherapy for pancreatic cancer with BRCA1/2 mutations, a majority of the patients who responded to rucaparib had which of the following characteristics?**
 - a. Platinum-sensitive or platinum-naïve disease**
 - Platinum-refractory disease